Want to see CTOR full AI Analyst Report?
Top Page
Citius Oncology
(NASDAQ:CTOR)
Select Model
Select Model
Rating:58Neutral
Price Target:
$1.00
▲(23.46% Upside)
Action:Reiterated
Date:09/19/26
The score is held back primarily by weak financial performance (no revenue, widening losses, and rising cash burn that increases financing risk). This is partially offset by strong technical momentum (price above major moving averages with positive MACD), while valuation contributes only modestly because a negative P/E and no dividend yield make valuation less supportive.
Positive Factors
LYMPHIR commercial uptake
Rapid growth in institutional accounts and wholesaler orders indicates that LYMPHIR is gaining real-world adoption in its launch market. Continued ordering expansion can build a broader commercial base, improve market presence, and support future topline growth if the trajectory persists.
Negative Factors
Dependence on external financing
Reliance on external financing makes the business dependent on continued access to capital before product economics are established. Financing requirements can constrain strategic flexibility and may create dilution or funding pressure if commercialization does not ramp quickly.
Read all positive and negative factors
Positive Factors
Negative Factors
LYMPHIR commercial uptake
Rapid growth in institutional accounts and wholesaler orders indicates that LYMPHIR is gaining real-world adoption in its launch market. Continued ordering expansion can build a broader commercial base, improve market presence, and support future topline growth if the trajectory persists.
Read all positive factors
Citius Oncology (CTOR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$106.00M
Dividend YieldN/A
Average Volume (3M)80.87K
Price to Earnings (P/E)―
Beta (1Y)2.82
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees285
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-0.48
Shares Outstanding92,981,200
10 Day Avg. Volume108,022
30 Day Avg. Volume80,871
Financial Highlights & Ratios
PEG Ratio-0.45
Price to Book (P/B)3.32
Price to Sales (P/S)0.00
P/FCF Ratio-27.08
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.00Price Target Upside393.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.52
Revenue Forecast (FY)$20.82M
Citius Oncology Business Overview & Revenue Model
Company Description
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling...
How the Company Makes Money
CTOR is a clinical-stage development company; publicly available information indicating recurring product revenue from approved and marketed therapies is null. As a result, the company’s operations are generally funded through external financing r...
Citius Oncology Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.11M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.77M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -43.13M | -23.49M | -20.57M | -12.12M | 0.00 |
| Net Income | -46.06M | -24.76M | -21.15M | -12.70M | -10.87M |
Balance Sheet | |||||
| Total Assets | 112.09M | 100.94M | 84.37M | 47.73M | 42.69M |
| Cash, Cash Equivalents and Short-Term Investments | 16.56M | 3.92M | 112.00 | 0.00 | 0.00 |
| Total Debt | 10.21M | 3.80M | 3.80M | 0.00 | 0.00 |
| Total Liabilities | 71.71M | 56.08M | 38.23M | 22.20M | 6.42M |
| Stockholders Equity | 40.38M | 44.87M | 46.14M | 25.54M | 36.27M |
Cash Flow | |||||
| Free Cash Flow | -19.71M | -5.49M | 126.35K | -601.30K | -47.97K |
| Operating Cash Flow | -19.71M | -5.49M | 126.35K | -601.30K | -47.97K |
| Investing Cash Flow | -12.93M | -5.75M | -5.00M | -1.32M | -67.32M |
| Financing Cash Flow | 49.48M | 15.17M | 4.87M | 1.66M | 67.66M |
Citius Oncology Technical Analysis
Positive
0.81
Price Trends
0.75
Positive
0.77
Positive
0.88
Positive
Market Momentum
0.08
Negative
73.71
Negative
89.71
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTOR, the sentiment is Positive. The current price of 0.81 is below the 20-day moving average (MA) of 0.86, above the 50-day MA of 0.75, and below the 200-day MA of 0.88, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 73.71 is Negative, neither overbought nor oversold. The STOCH value of 89.71 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CTOR.
Citius Oncology Risk Analysis
Citius Oncology disclosed 56 risk factors in its most recent earnings report. Citius Oncology reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Citius Oncology Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $31.84B | 37.94 | 4.52% | ― | 0.53% | -45.79% | |
63 Neutral | $6.52B | 14.24 | 8.43% | 3.85% | 6.84% | 61.67% | |
58 Neutral | $106.00M | -2.39 | -102.97% | ― | ― | ― | |
58 Neutral | $3.59B | 17.32 | 23.44% | 0.59% | -2.45% | -70.52% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $32.88M | -0.02 | -97.77% | 2.99% | ― | ― |
* Healthcare Sector Average
CTOR
Citius Oncology
1.14
-0.64
-35.96%
BIIB
Biogen
215.50
74.84
53.21%
GRFS
Grifols SA
7.31
-2.29
-23.81%
SRXH
SRx Health Solutions
1.67
-18.03
-91.52%
SCLX
Scilex Holding Company
5.04
-13.64
-73.02%
OGN
Organon
13.68
3.20
30.48%
Citius Oncology Corporate Events
Business Operations and StrategyExecutive/Board Changes
Citius Oncology adds independent director to expanded board
Positive
Aug 12, 2026
On August 10, 2026, Citius Oncology expanded its Board of Directors to nine members with the appointment of Jonathan Peri, Ph.D., J.D., as an independent director, following a unanimous Board vote earlier that month. The Board determined that Peri...
Business Operations and StrategyFinancial Disclosures
Citius Oncology reports strong LYMPHIR commercial momentum
Positive
Aug 5, 2026
On August 5, 2026, Citius Oncology reported strong commercial momentum for its CTCL therapy LYMPHIR, highlighting rapid growth in institutional uptake during the quarter ended June 30, 2026. New institutional accounts ordering LYMPHIR rose 78% qua...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.